Hims & Hers Health (NYSE:HIMS) Price Target Cut to $33.00 by Analysts at Citigroup

Hims & Hers Health (NYSE:HIMS) had its target price cut by stock analysts at Citigroup from $35.00 to $33.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Citigroup’s target price points to a potential upside of 6.70% from the company’s previous close.

A number of other analysts also recently issued reports on HIMS. Canaccord Genuity Group raised their target price on Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Jefferies Financial Group set a $24.50 price target on Hims & Hers Health in a report on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d)” rating on shares of Hims & Hers Health in a research report on Friday. UBS Group set a $23.00 target price on Hims & Hers Health in a research note on Friday, May 22nd. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Four investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $32.43.

Hims & Hers Health Trading Down 2.6%

Shares of HIMS traded down $0.84 during trading hours on Tuesday, hitting $30.93. 18,796,260 shares of the stock were exchanged, compared to its average volume of 26,787,123. The business has a 50-day moving average of $31.94 and a 200-day moving average of $26.07. Hims & Hers Health has a fifty-two week low of $13.74 and a fifty-two week high of $65.30. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. The firm has a market capitalization of $7.16 billion, a P/E ratio of -348.00, a price-to-earnings-growth ratio of 88.90 and a beta of 2.40.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The firm had revenue of $753.21 million during the quarter, compared to the consensus estimate of $698.89 million. During the same period in the previous year, the firm earned $0.17 earnings per share. The business’s quarterly revenue was up 38.2% on a year-over-year basis. On average, research analysts expect that Hims & Hers Health will post 0.03 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, Director David B. Wells purchased 48,400 shares of the stock in a transaction on Tuesday, May 26th. The shares were bought at an average price of $24.23 per share, for a total transaction of $1,172,732.00. Following the completion of the transaction, the director owned 224,417 shares of the company’s stock, valued at $5,437,623.91. This trade represents a 27.50% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, COO Michael Chi sold 14,027 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total transaction of $441,850.50. Following the transaction, the chief operating officer owned 432,124 shares of the company’s stock, valued at approximately $13,611,906. This trade represents a 3.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 83,126 shares of company stock worth $2,711,339. 11.76% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently made changes to their positions in HIMS. Vanguard Group Inc. lifted its holdings in shares of Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after purchasing an additional 1,407,651 shares during the last quarter. Munich Reinsurance Co Stock Corp in Munich acquired a new position in shares of Hims & Hers Health during the 4th quarter worth $11,187,000. Cunning Capital Partners LP purchased a new stake in shares of Hims & Hers Health in the fourth quarter valued at $1,110,000. Virtu Financial LLC acquired a new position in Hims & Hers Health in the 4th quarter valued at $1,937,000. Finally, Norges Bank acquired a new position in Hims & Hers Health during the fourth quarter worth approximately $62,153,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Second-quarter revenue rose 38% year over year to $753.2 million, exceeding analysts’ expectations of approximately $699 million. Strong subscriber growth and broader personalized-care offerings supported the result. Hims & Hers raises annual forecast revenue on strong subscriber growth
• Positive Sentiment: Hims & Hers raised its 2026 revenue forecast to $3.1 billion-$3.3 billion from $2.8 billion-$3.0 billion, while third-quarter revenue guidance of $880 million-$900 million also topped consensus. Management cited AI-driven engagement, specialty care expansion and international growth through Eucalyptus. HIMS Q2 Earnings Call Focuses on AI and Global Expansion
• Positive Sentiment: Needham raised its price target from $35 to $42 and maintained a “buy” rating, pointing to potential upside if the company’s growth investments translate into improved profitability. Needham price target update
• Neutral Sentiment: Bank of America increased its target from $30 to $32 but retained a “neutral” rating, indicating limited near-term upside at recent trading levels. Bank of America price target update
• Negative Sentiment: The company reported a quarterly loss of approximately $0.37 per share, substantially worse than the roughly $0.05 expected loss. Restructuring charges and investments related to branded GLP-1 weight-loss treatments and international expansion pressured profitability and reduced gross margin. Hims & Hers shares slide as costly weight-loss push squeezes margins
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations or alleged fiduciary-duty breaches involving Hims & Hers directors and officers. These announcements do not establish wrongdoing but add headline and litigation risk for shareholders. Kaplan Fox investigation announcement

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.